Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...

Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year survival rate of only 5%.

Ateganosine combined with Libtayo shows improved progression-free survival in advanced non-small cell lung cancer, suggesting potential long-term use. Spevatamig, a bispecific antibody, is being ...

Researchers have created tiny metal-based particles that push cancer cells over the edge while leaving healthy cells mostly unharmed. The particles work by increasing internal stress in cancer cells ...

Researchers at the University of Cologne discovered a new mechanism used by one of the most aggressive forms of lung cancer to escape treatment, paving the way for more efficient future therapies / pu ...